Vigabatrin versus carbamazepine and phenytoin in kainic acid-treated pubescent rats

Pharmacological Research

Volumn 36, Issue 2, 1997, Pages 87-93

  Mecarelli, Oriano ^a   De Feo, Maria Rita ^a   Del Priore, Daniele ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Carbamazepine; Kainic acid; Phenytoin; Seizures; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; KAINIC ACID; PHENYTOIN; VIGABATRIN;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG MECHANISM; EPILEPSY; EPILEPTIC STATE; INTRAPERITONEAL DRUG ADMINISTRATION; LETHALITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION; WET DOG SHAKES;

EID: 0031214034     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0184     Document Type: Article

References (50)

1. 1. Treiman DM. Gamma vinyl GABA: current role in the management of drug-resistant epilepsy. Epilepsia 1989; 30 (suppl. 3): S31-5.
2. 2. Dam M. Vigabatrin in refractory epilepsy in adults and its application in children. J Child Neurol 1991; 6 (Suppl. 2): S25-9.
3. 3. Grant SM, Heel RC. Vigabatrin - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1991; 41 (6): 889-926.
4. 4. Leppik IE. Antiepileptic drugs in development: prospects for the near future. Epilepsia 1994; 35 (suppl. 4): S29-40.
5. 5. Murri L, Iudice A. Vigabatrin as first add-on treatment in carbamazepine resistant epilepsy patients. Acta Neurol Scand 1995; 92 (suppl. 16): 40-7.
6. 6. French JA, Mosier M, Walker S, Sommerville K, Sussman N, Barry E, Bell W, Bergen D, Browne T, Ferrendelli J, Fisher R, Fromm G, Homan R, Krauss G, Lai CW, Leppik I, Leroy R, Pellock J, Penovich P, Ramsay RE, Shinnar S. A double blind, placebo-controlled study of Vigabatrin 3 g/day in patients with uncontrolled complex partial seizures. Neurology 1996; 46 (1): 54-61.
7. 7. de Feo MR, Mecarelli O, Marciani MG, Striano S, Tata MR, Ortenzi A, D'Alessandro P, Onofrj M, Marrelli A. Vigabatrin monotherapy: a multicenter open study with follow-up of 12 months. Boll Lega It Epil 1995; 91-92: 125-7.
8. 8. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52: 989-96.
9. 9. Tanganelli P, Regesta G. Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996; 25: 257-62.
10. 10. Schechter PJ, Tranier Y. Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice. Psychopharmacol 1977; 54: 145-8.
11. 11. Lenicque PM, Wepierre J, Cohen Y. Protection by 4-aminohex-5-enoic acid (γ-vinyl GABA) and hypobaric hypoxia against kainic acid neurotoxicity. Psychopharmacol 1979; 66: 51-3.
12. 12. Bernasconi R, Klein M, Martin P, Christen P, Hafner T, Portet C, Schmutz M. Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice. J Neural Transm 1988; 72: 213-33.
13. 13. Liu Z, Seiler N, Marescaux C, DePaulis A, Vergnes M. Potentiation of gamma-vinyl GABA (vigabatrin) effects by glicine. Eur J Pharmacol 1990; 182: 109-15.
14. 14. Sayin U, Cengiz S, Altug T. Vigabatrin as an anticonvulsant against pentylenetetrazol seizures. Pharmacol Res 1993; 28, 4: 325-31.
15. 15. Halonen T, Miettinen R, Toppinen A, Tuunanen J, Kotti T, Kiekkinen PJ. Vigabatrin protects against kainic acid-induced neuronal damage in rats hippocampus. Neurosci Lett 1995; 195: 13-6.
16. 16. Schechter PJ, Tranier Y, Jung MJ, Bohlen P. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA T inhibitors. Eur J Pharmacol 1977; 45: 319-28.
17. 17. Meldrum B, Horton R. Blockade of epileptic responses in the photosensitive baboon, Papio-papio, by two irreversible inhibitors of GABA Transaminase, gamma-Acetylenic GABA (4-amino-hex-5-enoic acid) and gamma vinyl GABA (4-amino-hex-enoic acid). Psychopharmacol 1978; 59: 47-50.
18. 18. Meldrum BS, Murugaiah K. Anticonvulsant action in mice with sound-induced seizures of the optical isomers of gamma vinyl GABA. Eur J Pharmacol 1983; 89: 149-52.
19. 19. Johnson DD, Wilcox R, Tuchek JM, Crawford RD. Experimental febrile convulsions in epileptic chickens: the anticonvulsant effect of elevated gamma-aminobutyric acid concentrations. Epilepsia 1985; 26: 466-71.
20. 20. Loscher W, Jackel R, Muller F. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling models. Eur J Pharmacol 1989; 163: 1-14.
21. 21. Marescaux C, Micheletti G, Vergnes M, Rimbach L, Warter JM. Diazepam antagonizes GABA mimetics in rats with spontaneous petit mal-like epilepsy. Eur J Pharmacol 1985; 113: 19-24.
22. 22. Nadler JV. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci 1981; 29: 2031-42.
23. 23. Ben Ari Y. Limbic seizures and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985; 14: 375-403.
24. 24. Cherubini E, de Feo MR, Mecarelli O, Ricci GF. Behavioral and electrographic patterns induced by systemic administration of kainic acid in developing rats. Dev Brain Res 1983; 9: 69-77.
25. 25. Albala BJ, Moshé SL, Okada R. Kainic acid-induced seizures: a developmental study. Dev Brain Res 1984; 13: 139-48.
26. 26. Tremblay E, Nitecka L, Berger ML, Ben Ari Y. Maturation of kainic acid seizure-brain damage syndrome in the rat. I. Clinical, electrographic and metabolic observations. Neuroscience 1984; 13: 1051-72.
27. 27. Holmes GL, Thompson JL. Effects of kainic acid on seizure susceptibility in the developing brain. Dev Brain Res 1988; 39: 51-9.
28. 28. Stafstrom CE, Thompson JL, Holmes JL. Kainic acid seizures in the developing brain: status epilepticus and spontaneous recurrent seizures. Dev Brain Res 1992; 65: 227-36.
29. 29. Nitecka L, Tremblay E, Charton G, Bouillot JP, Berger ML, Ben Ari Y. Maturation of kainic acid seizure-brain damage syndrome in the rat. II. Histopathological sequelae. Neuroscience 1984; 13: 1073-94.
30. 30. de Feo MR, Mecarelli O, Palladini G, Ricci GF. Long-term effects of early status epilepticus on the acquisition of conditioned avoidance behavior in rats. Epilepsia 1986; 27: 476-82.
31. 31. Sperber EF, Haas KZ, Stanton PK, Moshé SL. Resistance of the immature hippocampus to seizure-induced synaptic reorganization. Dev Brain Res 1991; 60: 88-93.
32. 32. Niedermeyer E. The Epilepsies. Diagnosis and Management. Baltimore: Urban and Schwarzenberg 1990: pp. 165-73.
33. 33. Skerrit JH, Johnston GAR, Chen Chow S. Interactions of the anticonvulsant carbamazepine with adenosine receptors. 2. Pharmacological studies. Epilepsia 1983; 24: 643-50.
34. 34. de Feo MR, Mecarelli O, Ricci GF, Rina MF. Effects of carbamazepine on bicuculline- and pentylenetetrazol-induced seizures in developing rats. Brain Dev 1991; 13: 343-7.
35. 35. Stankova L, Kubova H, Mares P. Anticonvulsant action of lamotrigine during ontogenesis in rats. Epilepsy Res 1992; 13: 17-22.
36. 36. Ben Ari Y, Lagowska Y, Le Gal La Salle G, Tremblay E, Ottersen OP, Naquet R. Diazepam pretreatment reduces distant hippocampal damage induced by intra-amygdaloid injections of kainic acid. Eur J Pharmacol 1978; 52, 3/4: 419-20.
37. 37. Fariello RG, Golden GT, Pisa M. Homotaurine (3 aminopropanesulfonic acid; 3 APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid. Neurology (NY) 1982; 32: 241-5.
38. 38. Clifford DB, Lothman EW, Dodson WE, Ferrendelli JA. Effect of anticonvulsant drugs on kainic acid-induced epileptiform activity. Exp Neurol 1982; 76: 156-67.
39. 39. Velisek L, Kubova H, Veliskova J, Mares P, Ortova M. Action of antiepileptic drugs against kainic acid-induced seizures and automatisms during ontogenesis in rats. Epilepsia 1992; 33 (6): 987-93.
40. 40. So EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW. Seizure exacerbation and status epilepticus related to carbamazepine-10, 11-epoxide. Ann Neurol 1994; 35: 6-10.
41. 41. Mares P, Liskova-Bernaskova K, Mudrochova M. Convulsant action of diphenylhydantoin overdose in young rats. Act Nerv Sup 1987; 29: 30-5.
42. 42. Osorio I, Burnstine TH, Remler B, Manon-Espaillat R, Reed RC. Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients. Epilepsia 1989; 30 (2): 230-4.
43. 43. Albertson TE, Peterson SL, Stark LG. Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in rats. Neuropharmacology 1980; 19: 643-52.
44. 44. Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 1995; 20: 93-104.
45. 45. Cavalheiro EA, Riche DA, Le Gal La Salle G. Long-term effects of intrahippocampal kainic acid injection in rats: a method for inducing spontaneous recurrent seizures. Electroencephalogr Clin Neurophysiol 1982; 53: 581-9.
46. 46. Cavalheiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneously recurrent seizures. Epilepsia 1991; 6: 778-82.
47. 47. Zaczek R, Nelson MF, Coyle ST. Effects of anesthetics and anticonvulsants on the action of kainic acid in the rat hippocampus. Eur J Pharmacol 1978; 52: 323-7.
48. 48. Fuller TA, Olney JW. Only certain anticonvulsants protect against kainate neurotoxicity. Neurobehav Toxicol Teratol 1981; 3: 355-61.
49. 49. Halonen T, Pitkanen A, Koivisto E, Partanen J, Riekkinen PJ. Effect of vigabatrin on the electroencephalogram in rats. Epilepsia 1992; 33 (1): 122-7.
50. 50. Mc Donald RL, Kelly KM. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994; 35 (suppl. 4): 41-50.